Market News & Trends
Ocugen Announces FDA Clearance of IND Amendment to Initiate Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 With a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400,…
Bio-Rad & Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers With Droplet Digital PCR
Bio-Rad Laboratories, Inc. recently announced a collaboration with Allegheny Health Network (AHN) aimed to generate clinical evidence across a range of cancer types to support…
PolTREG Identifies Promising Efficacy Biomarker for Type-1 Diabetes in Patients Treated With its Treg Therapy in Combination With Rituximab
PolTREG S.A. recemtly announced it has published data in International Immunopharmacology, which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset…
Medigene AG Secures European Patent for its iM-TCR Technology
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which…
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development
Biora Therapeutics, Inc. recently shared additional positive interim results from the single-ascending dose (SAD) clinical trial of BT-600, which is a drug-device combination consisting of…
Biognosys & Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma & Precision Medicine Research
Biognosys and Alamar Biosciences, Inc. recently announced a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers. This collaboration brings…
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Lipella Pharmaceuticals Inc. recently announced the US FDA has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for…
BioCorRx Pharmaceuticals Awarded New Patent for Novel Compound to Treat Pain, Depression & Schizophrenia
BioCorRx Inc. recently announced its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and…
OrganaBio Launches On-Demand GMP-Compliant Hematopoietic Stem Cell Source for Advanced Therapy Manufacturing
OrganaBio recently announced the launch of HematoPAC-HSC-CB-GMP, on-demand current good manufacturing practice (cGMP)-compliant CD34+ hematopoietic stem cells (HSCs) ethically derived from fresh human cord blood.…
Evaxion & Undisclosed Collaborator Announce Encouraging Results for Vaccine Antigens Against Staphylococcus Aureus Infection
Evaxion Biotech A/S recently announced the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….